MiMedx Q2 Call: $350M Sanara Acquisition Financing, Synergies, and Standalone Recovery Detailed
MDXG sits 26% above its 52-week low of $3.025.
Summary
MiMedx's Q2 call detailed the financing and synergy plan behind its $350M Sanara acquisition, projecting a combined company with >$400M revenue and 20%+ EBITDA margins in 2027, while standalone results showed a strong sequential recovery in wound care.
Key Events · M&A and Partnerships · MDXG
-
Acquisition Financing Secured
MiMedx secured a $300M six-year term loan from Hayfin Capital at SOFR + 6.25% to fund the Sanara acquisition, and initiated prepayment of its existing term loan with Citizens and Bank of America.
-
2027 Combined Financial Targets
Post-close, the combined company expects 2027 revenue well in excess of $400M, adjusted EBITDA margin of at least 20%, and rapid de-levering to under 3x adjusted EBITDA by year-end 2027.
-
Cost Synergy Breakdown
More than half of the expected $20M+ in annual cost synergies will come from G&A, with the remainder spread across other areas, driving immediate accretion.
-
Minimal Share Dilution
The deal will issue ~4.2M shares, but after prior buybacks of ~3.5M shares at $3.67, the net increase to the float is only about 700,000 shares.
Analysis · MDXG · Industrial Applications And Services
MiMedx's Q2 earnings call provides critical new details on its $350M acquisition of Sanara MedTech, including a $300M term loan at SOFR+6.25%, $20M+ in cost synergies (mostly G&A), and a net share increase of only ~700K after buybacks. The combined company is expected to generate over $400M in 2027 revenue with 20%+ adjusted EBITDA margins, rapidly de-levering. Standalone, MiMedx showed a 9% sequential revenue rebound to $64M, driven by 44% sequential wound care center volume growth, and reiterated its 2026 guidance. This call transforms the acquisition from a headline into a fully financed, synergy-backed plan with a clear path to profitability, making it highly market-moving.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.4% of the 495 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXG was trading at $3.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.